A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

類似資料

• A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy
  著者:: Lieu, Christopher, 等
  出版事項: (2008)
• Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias
  著者:: Gojo, Ivana, 等
  出版事項: (2007)
• A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors
  著者:: Chow, Laura Q. M., 等
  出版事項: (2007)
• ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma
  著者:: Batlevi, Connie Lee, 等
  出版事項: (2016)
• Histone Deacetylase Inhibitor MS-275 Exhibits Poor Brain Penetration: Pharmacokinetic Studies of [(11)C]MS-275 using Positron Emission Tomography
  著者:: Hooker, Jacob M., 等
  出版事項: (2009)